T Cell Immunity in SARS-CoV-2 Infections and Vaccination

T cell immunity constitutes a central pillar of the adaptive immune response to SARS-CoV-2, acting in concert with antibodies to prevent severe disease. CD4⁺ helper T cells orchestrate antiviral programmes by supporting B cell maturation and CD8⁺ cytotoxic T cells, which directly eliminate infected cells. Infection and vaccination both prime diverse repertoires of spike-specific T cells, generating central and effector memory subsets that persist for months and offer rapid recall upon re-exposure. Importantly, these T cells often recognise conserved epitopes beyond the spike protein, including polymerase and nucleocapsid regions, conferring cross-reactive potential to emerging variants. While systemic vaccination effectively induces circulating T cells, respiratory mucosal immunity remains limited without direct airway targeting. Pre-existing cross-coronavirus T cell populations can expand rapidly upon SARS-CoV-2 exposure, in some cases aborting infection before seroconversion. Collectively, these findings underscore the global significance of T cell responses for durable protection, inform next-generation vaccine design, and guide strategies to enhance mucosal and broad-spectrum cellular immunity.

Research from Nature Portfolio

One recent study evaluated an Omicron-specific self-amplifying mRNA booster, demonstrating robust expansion of spike-specific CD4⁺ and CD8⁺ T cells alongside heightened neutralising antibodies compared to prototype vaccines. Recipients exhibited durable T cell memory capable of cross-recognising the BA.1 variant, supporting tailored booster strategies. Another investigation of respiratory mucosal immunity revealed that individuals with both prior infection and vaccination maintain airway-resident memory CD4⁺ and CD8⁺ T cells for at least seven months, whereas vaccination alone induced minimal lung mucosal T cell populations. This work argues for intranasal or aerosolised vaccine platforms to enhance frontline cellular defence. A foundational report demonstrated that over 80 percent of vaccine- or infection-induced CD4⁺ and CD8⁺ T cells cross-recognise the heavily mutated Omicron spike, preserving functional cytokine production and cytotoxic capacity despite extensive antigenic drift.

T Cell Immunity in SARS-CoV-2 Infections and Vaccination publication trend

The graph below shows the total number of articles in t cell immunity in sars-cov-2 infections and vaccination across all publications each year (not limited to Nature Index journals).

Technical terms

CD4⁺ T cell: A helper T lymphocyte that coordinates antiviral immune responses through cytokine secretion and support of B cell and CD8⁺ T cell activities.

CD8⁺ T cell: A cytotoxic T lymphocyte that recognises and kills virus-infected cells via antigen presentation on MHC class I molecules.

Memory T cell: A long-lived lymphocyte subset formed after antigen exposure, capable of rapid reactivation upon re-encounter with the same pathogen.

Mucosal immunity: Immune defence mechanisms operating at mucous membranes, including tissue-resident T cells that provide frontline protection in the respiratory tract.

Cross-reactivity: The capacity of T cells to recognise and respond to related but distinct viral epitopes, often conserved across variants or related viruses.

References

1. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Nature Medicine (2024).
2. Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. Nature Communications (2023).
3. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature (2022).
4. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature (2021).
5. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell (2022).
6. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science (2021).
7. Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines. Immunological Reviews (2022).